> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts Samsung BLA for Avastin Biosimilar
- URL: https://www.fdaweb.com/fda-accepts-samsung-bla-for-avastin-biosimilar/
- Published: 2019-11-19T12:00:00.000Z
- Updated: 2026-09-14T15:53:33.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5145544

FDA has accepted for review a Samsung Bioepis BLA for SB8, a biosimilar candidate referencing Genentech’s Avastin (bevacizumab). Avastin is indicated for treating five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer. If approved, Samsung says the biosimilar will be commercialized in the U.S. by Merck.